News

Press Releases

Inflection Biosciences Announces Pre-clinical data for IBL-101 to be Presented at BSI Congress 2022

Dublin, Ireland, December 5, 2022 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...

Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence

ESCHBORN, Germany, May 30, 2022 Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd.,...

Inflection Biosciences Announces Expansion of Research into Autoimmune and Inflammatory Disease

Expands Advisory Panel with Immunology and Rheumatology Expertise Dublin, Ireland, May 27, 2022 Inflection Biosciences Ltd, a company...

Inflection Biosciences Announces Publication on Discovery of AUM302 in ACS Medicinal Chemistry

Dublin, Ireland, November 10, 2021 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...

Inflection Biosciences Announces Publication of Positive Pre-clinical Data for IBL-202 in CLL.

Dublin, Ireland, October 23, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...

Inflection Biosciences Announces Appointment of Gregory I. Berk, MD, to its Board of Directors.

Dublin, Ireland, October 19, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...

Inflection Biosciences Announces Publication of Positive Data for IBL-202 in DLBCL.

Dublin, Ireland, July 30, 2020 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...

Inflection Biosciences Announces the Appointment of Professor Martin Dreyling to its Advisory Panel.

Dublin, Ireland, June 4, 2020 Inflection Biosciences Ltd, a company developing innovative small molecule therapeutics for the treatment...

Inflection Biosciences Announces Participation at Upcoming Industry Conferences.

Dublin, Ireland, May 12th, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...

Inflection Biosciences Announces Appointment of Shaun McNulty, Ph.D., as Chief Scientific Officer.

Dublin, Ireland, February 19th, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of...